AR047747A1 - Moduladores de furosemida de hm74 - Google Patents

Moduladores de furosemida de hm74

Info

Publication number
AR047747A1
AR047747A1 ARP050100596A ARP050100596A AR047747A1 AR 047747 A1 AR047747 A1 AR 047747A1 AR P050100596 A ARP050100596 A AR P050100596A AR P050100596 A ARP050100596 A AR P050100596A AR 047747 A1 AR047747 A1 AR 047747A1
Authority
AR
Argentina
Prior art keywords
contain
substituted
combinations
heteroatom
branched
Prior art date
Application number
ARP050100596A
Other languages
English (en)
Spanish (es)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR047747A1 publication Critical patent/AR047747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP050100596A 2004-02-20 2005-02-18 Moduladores de furosemida de hm74 AR047747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
AR047747A1 true AR047747A1 (es) 2006-02-15

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100596A AR047747A1 (es) 2004-02-20 2005-02-18 Moduladores de furosemida de hm74

Country Status (24)

Country Link
US (2) US7232811B2 (cg-RX-API-DMAC7.html)
EP (1) EP1718292A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007523166A (cg-RX-API-DMAC7.html)
KR (1) KR20060127141A (cg-RX-API-DMAC7.html)
CN (1) CN1921845A (cg-RX-API-DMAC7.html)
AR (1) AR047747A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005216879B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0506792A (cg-RX-API-DMAC7.html)
CA (1) CA2557444A1 (cg-RX-API-DMAC7.html)
CR (1) CR8528A (cg-RX-API-DMAC7.html)
EC (1) ECSP066777A (cg-RX-API-DMAC7.html)
IL (1) IL177086A (cg-RX-API-DMAC7.html)
MA (1) MA28373A1 (cg-RX-API-DMAC7.html)
ME (1) MEP21108A (cg-RX-API-DMAC7.html)
MX (1) MXPA06008612A (cg-RX-API-DMAC7.html)
NO (1) NO20064237L (cg-RX-API-DMAC7.html)
NZ (1) NZ548830A (cg-RX-API-DMAC7.html)
RS (1) RS20060473A (cg-RX-API-DMAC7.html)
RU (1) RU2006133540A (cg-RX-API-DMAC7.html)
SG (1) SG164305A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN06234A1 (cg-RX-API-DMAC7.html)
TW (1) TW200538109A (cg-RX-API-DMAC7.html)
WO (1) WO2005082350A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606679B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
WO2007079470A2 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
WO2007084450A2 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
EP2086329B1 (en) 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) * 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
AT324318B (de) * 1971-02-15 1975-08-25 Dumex Ltd As Verfahren zur herstellung von furanderivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
AU7966098A (en) * 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
WO2005082350A1 (en) 2005-09-09
AU2005216879B2 (en) 2009-12-10
CA2557444A1 (en) 2005-09-09
MA28373A1 (fr) 2006-12-01
US20070213391A1 (en) 2007-09-13
JP2007523166A (ja) 2007-08-16
NZ548830A (en) 2010-03-26
NO20064237L (no) 2006-09-19
BRPI0506792A (pt) 2007-05-22
AU2005216879A1 (en) 2005-09-09
WO2005082350A8 (en) 2005-12-08
CN1921845A (zh) 2007-02-28
US7556931B2 (en) 2009-07-07
ZA200606679B (en) 2008-01-30
TNSN06234A1 (en) 2007-12-03
EP1718292A1 (en) 2006-11-08
RS20060473A (sr) 2008-08-07
TW200538109A (en) 2005-12-01
MXPA06008612A (es) 2007-01-25
MEP21108A (en) 2010-06-10
RU2006133540A (ru) 2008-03-27
US7232811B2 (en) 2007-06-19
IL177086A (en) 2010-06-16
IL177086A0 (en) 2006-12-10
CR8528A (es) 2007-06-08
SG164305A1 (en) 2010-09-29
ECSP066777A (es) 2006-11-16

Similar Documents

Publication Publication Date Title
BRPI0414541B8 (pt) compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
AR107966A2 (es) Derivados de pirimidina y piridina inhibidores de la proteína quinasa
CO5550436A2 (es) Derivados de benzamida
DE59608740D1 (de) Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
ECSP077273A (es) Moduladores de quinasa de anillo heterocíclico fusionado
DE3879292D1 (de) Substituierte aromatische sulfonamide als mittel gegen glaukom.
BR0114657A (pt) Compostos de benzamida e seu uso
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
EP1267616A4 (en) METHOD FOR MODULATING HAIR GROWTH
ES2037752T3 (es) Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion.
PE20141280A1 (es) Inhibidores de aplicacion viral
PE20040581A1 (es) Inhibidores heterociclicos de cinasas
UY26130A1 (es) Compuestos para tratar la obesidad
AR065784A1 (es) Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
CY1109954T1 (el) Διαδερμικο θεραπευτικο συστημα (tts) με τη δραστικη ουσια φεντανυλη
AR018204A1 (es) METODO PARA LA PREPARACIOON DE CITALOPRAM , INTERMEDIARIO PARA LA PREPARACION DE CITALOPRAM Y EL USO DEL INTERMEDIARIO PARA LA PREPARACIoN DE CITALOPRAM
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
UY28186A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos.
CO6321264A2 (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
AR121275A1 (es) Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamento
ECSP055918A (es) Procedimiento para modificar la formación de cristal de fármaco

Legal Events

Date Code Title Description
FA Abandonment or withdrawal